8-K: Lineage Cell Therapeutics Announces $39.9 Million At-The-Market Offering

Lineage Cell Therapeutics has filed a prospectus supplement for an at-the-market offering of common shares, aiming to raise up to $39.9 million.

Summary

• Lineage Cell Therapeutics has announced an at-the-market (ATM) offering of its common shares.
• The company intends to sell up to $39,966,424 worth of shares through B. Riley Securities, Inc.
• This offering is part of a shelf registration statement previously filed with the SEC on March 7, 2024, and declared effective on May 14, 2024.
• The shares will be offered and sold under the terms of a sales agreement dated March 22, 2024.
• The legal opinion regarding the validity of the shares is provided by Sheppard Mullin Richter & Hampton, LLP.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It details a standard capital raising activity, which is necessary for the company's operations, but also introduces potential dilution for existing shareholders.

Positives

• The company has secured a mechanism to raise up to $39.9 million in capital through an at-the-market offering.
• The legal opinion from Sheppard Mullin Richter & Hampton, LLP provides assurance on the validity of the shares.
• The offering is being conducted through a well-established sales agent, B. Riley Securities, Inc.

Risks

• The company's stock price could be negatively impacted by the dilution caused by the issuance of new shares.
• There is no guarantee that the company will be able to sell all of the offered shares at the desired price.
• The market conditions could affect the success of the offering.

Future Outlook

The company intends to sell common shares from time to time through B. Riley Securities, Inc., as market conditions allow, to raise up to $39.9 million.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital without the need for a large, single offering. This allows for more flexibility in timing and pricing.

Comparison to Industry Standards

• Many biotech companies use ATM offerings to raise capital, especially when they have ongoing research and development needs.
• The size of this offering, approximately $40 million, is within the typical range for similar companies at this stage of development.
• Companies like Geron Corporation and BioTime (now AgeX Therapeutics) have also used ATM offerings to fund their operations and clinical trials.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company will have additional capital to fund its operations and research.
• The offering could impact the company's stock price.

Next Steps

• The company will continue to offer and sell shares through B. Riley Securities, Inc. as market conditions allow.
• The company will use the proceeds from the offering for general corporate purposes.

Key Dates

Keywords

at-the-market offering, common shares, capital raise, shelf registration, B. Riley Securities, Lineage Cell Therapeutics, securities offering